Nine Years of Building Trusted Infrastructure for Wallets and Payments, for Humans and AI Agents

SINGAPORE, October 14, 2026 – Cobo, a trusted digital asset infrastructure company, today marks its ninth anniversary with “9 Stories,” a series of short films featuring founders, clients, partners, and team members sharing their experiences and perspectives in their own words. After nine years of delivering Wallet-as-a-Service (WaaS) and multi-chain solutions, Cobo has served more than 680 clients across nearly 50 countries and regions.

Founded in 2017 by blockchain pioneers Discus Fish and Dr. Changhao Jiang, Cobo has built trusted infrastructure with a focus on operational efficiency and risk management.

“What I hope never changes is our commitment to prioritizing long-term value over short-term trends, and making decisions about what to build based on what creates real value for our users,” said Dr. Changhao Jiang, Co-founder & CTO.

That philosophy continues to guide Cobo as it responds to emerging shifts in how digital assets are used and managed. In 2026, AI tools are enabling organizations to automate complex workflows and reduce reliance on traditional software while creating demand for secure, enforceable ways for AI agents to hold assets, execute payments, and manage treasury on-chain.

Cobo’s response is the Cobo Agentic Wallet (CAW), launched earlier this year as a non-custodial-by-default, MPC-secured wallet purpose-built for AI agents. It allows autonomous on-chain operations within human-defined boundaries enforced at the infrastructure level.

“To our clients: thank you for trusting Cobo and giving us the room to keep iterating. I believe a better future, perhaps beyond what we can imagine today, lies ahead, and we look forward to building it together,” said Discus Fish, Co-founder & CEO.

As it marks its ninth anniversary, Cobo looks back on key milestones, including a $13 million Series A in 2018, a $40 million Series B+ led by DST Global, IMO Ventures, and A&T Capital in 2021, the launch of WaaS, SOC 2 Type II (Big Four audited), and ISO 27001 certification.

New stories from the “9 Stories” series will be released over the coming weeks starting today. Watch them at https://www.cobo.com/9th.

About Cobo

Founded in 2017 and headquartered in Singapore, Cobo builds trusted infrastructure for wallets and payments, for humans and AI agents, with licensed entities in Hong Kong, Canada, and the United States. Cobo is SOC 2 Type II (Big Four audited) and ISO 27001 certified, and has secured billions in client assets with zero security incidents since 2017.

Visit https://www.cobo.com for more information.

Fomboni, Comoros, October 14th, 2026, FinanceWire

Investors In 50+ Countries Can Now Follow Verified Traders Automatically, Through The Mt4, Mt5 Or Dxtrade Account They Already Own

FX Junction, the social and copy trading platform, is making professional-grade trading strategies accessible to anyone with a brokerage account. Investors connect their existing MetaTrader 4, MetaTrader 5 or DXtrade account, choose from a roster of verified signal providers, and see those providers’ trades mirrored in their own account in real time. The model rests on one simple promise: FX Junction never holds client money. Every dollar stays with the investor’s own broker, under the investor’s own control.

Trading Stops Being A Solitary Pursuit

For years, retail trading has meant one person alone with a screen full of charts. FX Junction is built on the opposite idea. Its global community connects beginners and seasoned professionals, young and old, so that strategies, insight and experience can be shared across borders. A newcomer no longer has to learn everything the hard way; they can follow traders whose full record is public.

Up and running in four steps

• Create an account. Registration takes minutes and requires no prior trading experience.
• Connect an existing account. Investors link an MT4, MT5 or DXtrade account from virtually any major broker.
• Choose whom to follow. Each signal provider has a verified performance history, with detailed analytics covering more than five years of data.
• Let the platform do the work. Trades are replicated automatically, with latency the company puts below 0.1 seconds.

Built For Control, Not Blind Faith

FX Junction gives investors the tools to decide how much risk they take on. Position sizing, stop-loss settings and AI-assisted risk controls sit alongside 24/7 portfolio monitoring, live notifications and full reporting. Users can copy several traders at once across Forex, stocks, indices and commodities, more than 150 instruments in total, building a diversified portfolio from a single dashboard.

Because funds never move to FX Junction, investors keep the broker relationship they already trust. They can trade independently alongside their copied positions at any time.

More Than A Copy Button

FX Junction pairs automation with education and research. Its free Education Hub offers short courses on signal-provider analytics, the psychology of copying, and portfolio architecture. Daily market news, live technical analysis with entry, stop-loss and take-profit levels, and monthly model equity portfolios keep members informed. The October 2026 portfolio, for example, focuses on ten companies in nuclear generation, grid equipment and data-center power, the infrastructure behind surging AI electricity demand.

For investors who want a guiding hand, FX Junction offers annual support packages from $199 to $1,999 per year. Every tier includes MetaTrader and DXtrade training, performance-based guidance on signal providers, portfolio and diversification consultation, and risk and money management. Higher tiers add technical and fundamental analysis training, company results briefings and alerts when the investment outlook changes.

Experienced traders can also join the other side of the platform as signal providers, while businesses can work with FX Junction through API, white-label and referral programs.

About FX Junction

FX Junction is a social and copy trading platform that lets investors automatically replicate the trades of verified signal providers in their own MT4, MT5 or DXtrade accounts. Available in more than 50 countries and compatible with over 1,000 brokers, it combines automated copying with risk controls, market research and education, while client funds remain at the investor’s own broker. FX Junction is operated by FXJ LTD, Bonovo Road, P.B. 1257, Fomboni, Island of Mohéli, Comoros Union.

Learn more at fxjunction.com.

Risk warning: Trading leveraged products carries a high level of risk and may not be suitable for all investors. Past performance is no guide to future results, and investors may get back less than they invested. FX Junction does not provide investment advice. Company figures cited are as reported on fxjunction.com as of October 12, 2026.

Contact

Team of analysts
support@fxjunction.com

Boca Raton, Florida, October 14th, 2026, FinanceWire

• Collaboration combines INmune Bio’s clinical research with QCi’s Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
• Initial engagement marks QCi’s first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio’s investigational treatment for Alzheimer’s disease and other disease conditions.

The collaboration brings together INmune Bio’s data from pre-clinical research through four clinical trials and understanding of disease biology with QCi’s Dirac-3S quantum optimization machine. Working with clinical and publicly available biomedical datasets, the companies intend to use quantum computing alongside AI and conventional data analytics to uncover relationships that could help find diseases driven by the same biology XPro targets, and to prioritize those with the greatest potential for success.

The Stage 1 engagement represents QCi’s first commercial customer in the pharmaceutical and biotechnology market. The agreement also provides options for additional work as INmune Bio advances its clinical development programs.

“We’ve built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro,” said David Moss, Chief Executive Officer of INmune Bio. “This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets. We’ll look for the diseases with the greatest potential for success, those whose human biology matches what we’ve already seen XPro do, starting with rare diseases where trials can be smaller, faster and more capital-efficient, and where qualifying pediatric approvals may earn a Priority Review Voucher.”

Together, the companies will build on INmune Bio’s research into XPro to explore where its approach to targeting inflammation may offer the greatest potential. XPro is designed to selectively inhibit soluble tumor necrosis factor (TNF), a protein involved in inflammation, while preserving other TNF functions important to the immune system. INmune Bio is investigating its potential in neurological and rare diseases where this targeted approach may offer a therapeutic benefit.

Using its Dirac-3S entropy quantum optimization machine alongside AI and conventional analytics, QCi will look for patterns and relationships across these datasets that could help researchers better understand treatment responses, identify promising patient populations and prioritize new indications for further study.

“This is a great example of what practical quantum computing can look like today,” said Yuping Huang, Chairman and Chief Executive Officer of QCi. “INmune Bio has a complex scientific problem and a substantial body of clinical and biological data. Our job is to bring new computing capabilities to that problem and see what we can learn. The potential to help researchers make better decisions about future treatments is exciting, and it opens an important new market for QCi.”

An important part of the program will be testing where quantum optimization adds value. The companies plan to compare results from QCi’s quantum optimization machine with appropriate conventional statistical and machine-learning methods, evaluating which approaches are best suited to different parts of the analysis.

The work is also intended to establish a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications.

For INmune Bio, the collaboration offers a new way to evaluate the broader potential of XPro and prioritize future development opportunities. For QCi, it represents an opportunity to showcase how its room-temperature, low-power quantum computing technology can be applied to complex, real-world problems in pharmaceutical research.

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

• CORDStrom: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
• XPro1595: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595 is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

About Quantum Computing Inc.

Quantum Computing Inc. (Nasdaq: QUBT) is an integrated quantum photonics company developing and manufacturing technologies that use light to compute complex information, capture hard-to-detect signals and communicate more securely. QCi brings together quantum optics, integrated photonics, semiconductor manufacturing and advanced packaging to create a more direct path from advanced science to practical products.

QCi’s portfolio includes quantum machines, photonic chips, components, modules and subsystems, as well as foundry and advanced manufacturing services. Its technologies are designed to operate at room temperature and low power, without the specialized cooling infrastructure required by many quantum approaches. These advantages enable deployment across computing and AI, secure communications, sensing and imaging, aerospace and defense, and other demanding applications.

Headquartered in Hoboken, New Jersey, QCi has operations across the United States. By combining advanced physics, device engineering and scalable manufacturing, QCi is working to make quantum and advanced photonic technologies more accessible and useful in the real world.

To learn more about QCi and its approach to harnessing light for practical quantum computing, please visit www.quantumcomputinginc.com.

Forward Looking Statements:

InMune Bio Inc.

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel, XPro and INKmune trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom, XPro1595 (XPro, pegipanermin), and INKmune have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

Quantum Computing Inc.

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “enhance,” “intends,” “goal,” “objective,” “seek,” “attempt,” “aim to,” or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including QCi’s ability to use quantum optimization to analyze biomedical data, whether collaboration will generate relevant and valuable insights, the performance of the Dirac-3S in the intended application, the ability of quantum optimization to contribute to the development of new treatments, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward- looking statements to reflect changed conditions.

Contacts

Head of Investor Relations
Daniel Carlson
dcarlson@inmunebio.com
Head of Investor Relations
David Moskowtiz
investors@quantumcomputinginc.com